Geneva, Switzerland, 22 February, 2018 – 6:30pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that GNbAC1 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune neurological disorder of the peripheral nervous system. In the US, the prevalence rate of CIDP is estimated to be 9 cases per 100,000. Current long-term therapy is often limited by side effects and one-third of patients are refractory to existing treatments.
For more information :
http://www.geneuro.com/data/news/geneuro-pr-cidp-us-orphandesignation-en.pdf
